The persistence and clearance of viral RNA in 2019 novel coronavirus disease survivors

Yun Ling,Shuibao Xu,Yixiao Lin,Di Tian,Zhaoqin Zhu,Fahui Dai,Fan Wu,Zhigang Song,Wei Huang,Jun Chen,Bijie Hu,Sheng Wang,Enqiang Mao,Lei Zhu,Wenhong Zhang,Hongzhou Lu

2020-01-01

Abstract:Objective: To analyze the clearance time and the influencing factors of 2019-nCoV RNA in different samples from the patients with 2019 novel coronavirus disease (COVID-19), which may provide further evidence to improve the management of the patients during convalescence. Methods: The clinical data and the laboratory test results of convalescent patients with COVID-19, who were admitted to Shanghai Public Health Clinical Center from January 20, 2020 to February 10, 2020, were collected retrospectively. The RT-PCR results for patients’ oropharyngeal swab, stool, urine, and serum samples were collected and analyzed. The convalescent patients refer to the recovered non-fever cases without respiratory symptoms, and had two successive(upon 24h sampling interval) negative RT-PCR results of viral RNA for oropharyngeal swabs. The effects of CD4 + T lymphocytes, inflammatory indicators, and glucocorticoid treatment on viral nucleic acid clearance were analyzed. Result: In the 292 confirmed cases, 66 patients recovered after treatment, and were included in our study. Totally 28(42.4%) females and 38 males (57.6%) with a median age of 44.0 (34.062.0) year-old were analyzed. After in-hospital treatment, patients’ inflammation indicators decreased with improved clinical condition. The median time from the onset of symptoms to first negative RT-PCR results for oropharyngeal swabs of convalescent patients was 9.5 (6.011.0) days. By the time of February 10, 2020, 11 convalescent cases (16.7%) still tested positive for viral RNA in stool specimens, and the other 55 patients’ stool specimens turned negative for 2019-nCoV with median duration of 11.0(9.0-16.0)days. Among these 55 patients, 43 cases had longer duration for stool specimens detected negative for viral RNA than throat swabs, with median delay of 2.0 (1.0-4.0) days. The positivity of viral nucleic acid test for urine samples was low with only 4 (6.9%) positive results in 58 cases, viral RNA in 3 patients’ urine specimens remained tested positive after throat swabs turned negative. Using multiple linear regression model, the analysis showed the CD4 + T lymphocyte counts may help predict the the duration of viral RNA detection in patients’ stool (P = 0.01). The duration of viral RNA detection for oropharyngeal swabs and feces in the corticosteroid treatment group was longer than that in the non-corticosteroid treatment group, which were 15 days vs 8.0 days (P = 0.013) and 20 days vs 11 days (P <0.001), respectively. There was no statistically significant difference on the inflammation indicators between patients with positive fecal viral RNA test results and the negative group (P> 0.05). Conclusion: In brief as the clearance of viral RNA in patients stool was delayed comparing to oropharyngeal swabs, it is important to detect the viral RNA in feces during the convalescence. As the delayed clearance of viral RNA in corticosteroid treatment group, corticosteroids is not recommended in the treatment of COVID-19, especially for the mild conditions cases. The duration of RNA detection may relate to the host cell immunity.